Experienced in Non-Small Cell Lung Cancer (NSCLC)

Dr. Rhonda L. Bitting

Oncology | Hematology Oncology | Hematology
Medical Center Blvd Hematology And Oncology, 
Winston Salem, NC 
Experienced in Non-Small Cell Lung Cancer (NSCLC)
Medical Center Blvd Hematology And Oncology, 
Winston Salem, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rhonda Bitting is an Oncologist and a Hematologist Oncology provider in Winston Salem, North Carolina. Dr. Bitting is rated as an Experienced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Prostate Cancer, Penile Cancer, Melanoma, Tissue Biopsy, and Prostatectomy.

Her clinical research consists of co-authoring 51 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Hematology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Medical Center Blvd Hematology And Oncology, Winston Salem, NC 27157

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 2 Double-blind, Placebo-controlled Study of the Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy
A Phase 2 Double-blind, Placebo-controlled Study of the Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy
Enrollment Status: Completed
Publish Date: September 30, 2025
Intervention Type: Other, Drug
Study Drug: Muscadine grape extract
Study Phase: Phase 2
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
Enrollment Status: Completed
Publish Date: March 19, 2024
Intervention Type: Drug, Radiation
Study Drugs: Apalutamide, Androgen deprivation, Docetaxel
Study Phase: Phase 2
Single-Arm Phase II Combination Study of Low-Dose Paclitaxel With Pembrolizumab in Platinum-Refractory Urothelial Carcinoma
Single-Arm Phase II Combination Study of Low-Dose Paclitaxel With Pembrolizumab in Platinum-Refractory Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Other, Drug, Biological
Study Drugs: Paclitaxel, Pembrolizumab
Study Phase: Phase 2
Correlation of Serum Catecholamine With Emotional Stress in Men With Prostate Cancer: A Pilot Study
Correlation of Serum Catecholamine With Emotional Stress in Men With Prostate Cancer: A Pilot Study
Enrollment Status: Completed
Publish Date: March 10, 2022
Intervention Type: Other, Procedure
Feasibility Study of a Home-Based Exercise Intervention Program for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)
Feasibility Study of a Home-Based Exercise Intervention Program for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)
Enrollment Status: Completed
Publish Date: April 20, 2021
Intervention Type: Behavioral
Study Phase: Not Applicable
A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: December 09, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard Therapy With Sipuleucel-T (Provenge®) in Pts w/ Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer(mCRPC)
Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard Therapy With Sipuleucel-T (Provenge®) in Pts w/ Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer(mCRPC)
Enrollment Status: Completed
Publish Date: July 09, 2019
Intervention Type: Biological, Other
Study Phase: Phase 2
View 7 Less Clinical Trials

51 Total Publications

Factors Affecting Genomic Testing in Prostate Cancer: Results From the Decision-Making, Experience, and Confidence In Determining Genomic Evaluation (DECIDE) Survey.
Factors Affecting Genomic Testing in Prostate Cancer: Results From the Decision-Making, Experience, and Confidence In Determining Genomic Evaluation (DECIDE) Survey.
Journal: JCO precision oncology
Published: May 15, 2025
Similar Doctors
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Mohamed K. Mohamed
Hematology | Oncology
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Mohamed K. Mohamed
Hematology | Oncology

The Moses H Cone Memorial Hospital Operating Corporation

501 N Elam Ave, 
Greensboro, NC 
 (23.4 miles away)
336-832-1100
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Mohamed Mohamed is a Hematologist and an Oncologist in Greensboro, North Carolina. Dr. Mohamed is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, and EGFR Positive Lung Cancer. Dr. Mohamed is currently accepting new patients.

Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. William J. Petty
Hematology Oncology | Hematology | Oncology
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. William J. Petty
Hematology Oncology | Hematology | Oncology

Wake Forest University Health Sciences

365 Brookdale Dr, 
Statesville, NC 
 (41.2 miles away)
704-872-3630
Languages Spoken:
English
See accepted insurances
Accepting New Patients

William Petty is a Hematologist Oncology specialist and a Hematologist in Statesville, North Carolina. Dr. Petty is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Thymic Epithelial Tumor, Pleuropulmonary Blastoma, Lung Adenocarcinoma, Advanced Bronchoscopy, and Bone Marrow Aspiration. Dr. Petty is currently accepting new patients.

Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Thomas W. Lycan
Hematology Oncology | Hematology | Oncology
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Thomas W. Lycan
Hematology Oncology | Hematology | Oncology

Wake Forest University Health Sciences

Medical Ctr Blvd, 
Winston Salem, NC 
 (1.6 miles away)
336-716-2734
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Thomas Lycan is a Hematologist Oncology specialist and a Hematologist in Winston Salem, North Carolina. Dr. Lycan is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Ewing Sarcoma, and Gamma Knife Radiosurgery. Dr. Lycan is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bitting's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile